Neuland Laboratories Ltd (NSE:NEULANDLAB)
₹ 22,216 -639 (-2.8%) Market Cap: 284.74 Bil Enterprise Value: 284.49 Bil PE Ratio: 57.23 PB Ratio: 15.20 GF Score: 86/100

Q4 2025 Neuland Laboratories Ltd Earnings Call Transcript

May 15, 2025 / 11:30 AM GMT
Release Date Price: ₹11859 (-4.93%)

Key Points

Positve
  • Neuland Laboratories Ltd (BOM:524558) has commercialized a new production block in Unit 3, which is expected to boost revenue momentum in the latter half of FY 526.
  • The company has a strong reputation in the CDMO business, which is attracting increased interest from customers looking to partner for innovative medicines.
  • Neuland Laboratories Ltd (BOM:524558) has invested in capacity building for existing and new molecules, indicating a commitment to future growth.
  • The company has a negative net debt position, reflecting strong financial management and a focus on optimizing working capital.
  • There is a healthy pipeline of CMS projects, with expectations of commercializing new molecules in FY 526, which could drive future growth.
Negative
  • Total income decreased by 14% year-on-year, indicating a challenging financial performance for the quarter.
  • Gross margins have declined from 58.8% in Q4 FY 524 to 56.3% in Q4 FY 525, impacting profitability.
  • The CMS segment experienced a significant downturn in FY 525 due to the natural life cycle of products, affecting overall revenue.
  • The company faces uncertainties related to US tariffs, which could impact revenue from its significant US market exposure.
  • Neuland Laboratories Ltd (BOM:524558) has not provided specific guidance on future growth, citing the inherent variability and unpredictability of its business.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NEUL.NS - Neuland Laboratories Ltd
Q4 2025 Neuland Laboratories Ltd Earnings Call
May 15, 2025 / 11:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to Newland Laboratories Limited Q4 and F 525 earning conference call. As a reminder, all participant lines will be in the lesson only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing 0 on a touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Ravio Teshi from Oa.

Thank you and over to you, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-------------------------------------------------------------------------
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot